Patient Education, Setting Expectations, and Dose Modifications

Prophylaxis works only when patients treat it as part of a daily routine, says Amanda Edmond, PA-C, of Banner MD Anderson Cancer Center at Banner Gateway Medical Center, discussing amivantamab plus lazertinib in EGFR-mutated non-small cell lung cancer. Rather than waiting for rash to appear, her clinic acts as soon as the treatment decision is made, using an education visit and handouts to frame prevention as routine, comparable with taking a vitamin or brushing teeth. She encourages colleagues to sit down with patients and be real with them, presenting the upfront work as empowering because patients can do something to help themselves and their outcome, which matters to patients with EGFR mutations, who tend to be younger and often still working. Many patients require a dose interruption or reduction, and MARIPOSA showed efficacy remained consistent despite modifications, so Edmond treats dosing as adaptable and works to find the right dose for each individual.